AbbVie Announces Advances in Rheumatic Disease R&D at APLAR 27

AbbVie Showcases Research Progress at APLAR 27

AbbVie, headquartered in Minato-ku, Tokyo, is presenting their latest advancements in research and development for rheumatic diseases during the 27th Asia-Pacific League of Associations for Rheumatology (APLAR) conference, taking place from September 3 to 7 in Fukuoka. This event underscores AbbVie's commitment toward improving treatment standards for rheumatic diseases across the Asia-Pacific region.

Throughout the conference, AbbVie is co-hosting a series of workshops and two satellite symposia, demonstrating its dedication to discovering and delivering diverse and innovative solutions for managing rheumatic conditions. Magdy Eltabbakh, the Intercontinental Immunology Medical Head at AbbVie, emphasizes the company's efforts in the past two decades to elevate treatment standards for patients with rheumatic diseases and to contribute to disease management and progression control. He notes, "In Asia, there are regional disparities in access to treatment and understanding of the diseases. AbbVie is focusing on enhancing the understanding of the importance of early treatment and the 'Treat to Target' concept, actively supporting diverse patient activities."

Presentations During APLAR 27

AbbVie plans to deliver one oral presentation and present eight poster presentations, with topics as follows:

1. Long-term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: 7-year Data from SELECT-COMPARE (Oral Presentation)
2. Real-world Effectiveness and Patient Satisfaction of Risankizumab in Early Psoriatic Arthritis Treatment in Treatment-Naive Patients (Survey Data from the US and Europe)
3. Long-term Safety and Efficacy of Upadacitinib in Patients with Psoriatic Arthritis: 5-year Results from Phase III SELECT-PsA 1 Study
4. Long-term Safety of Upadacitinib in Rheumatoid Arthritis, Psoriatic Arthritis (PsA), and Axial Spondyloarthritis (axSpA), including clinical trial data from approximately 17,000 patient-years
5. Achievement of Treatment Goals and Maintenance of Response with Upadacitinib in Patients with Moderate to Severe Rheumatoid Arthritis: Final 2-Year Results from the UPHOLD Study
6. Analysis of 24-week Post-Marketing Surveillance of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: Mid-2024 Interim Report
7. Effectiveness of Upadacitinib in Real-world Settings for Australian Patients with Rheumatoid Arthritis: 24-Month Subgroup Analysis from the UPHOLD Observational Study
8. Retrospective Analysis of Persistence, Effectiveness, and Treatment Patterns of Upadacitinib in over 2,600 Australian Patients with Rheumatoid Arthritis Using OPAL Dataset

Additionally, AbbVie will co-host the pre-congress workshop sponsored by GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) focusing on axial spondyloarthritis, difficult-to-treat psoriatic arthritis, and advancements in MRI technology. This all-day program aims to improve diagnosis and patient outcomes in spondyloarthritis through interactive sessions and in-depth discussions led by international and regional experts.

Satellite Symposia

Furthermore, two satellite symposia co-hosted by AbbVie will discuss treatment strategies to achieve targets and the benefit/risk profile of Upadacitinib in rheumatic diseases. Topics include the importance of achieving clinical remission and the significance of shared decision-making. Recent results of the SELECT trials in rheumatoid arthritis and giant cell arteritis will also be shared during these sessions.

About AbbVie

AbbVie's mission is to develop and deliver innovative medicines that address serious health issues and tackle challenging medical problems for the future. The company is committed to enhancing individual lives by focusing on key areas including immune diseases, cancer, neuroscience, eye care, and aesthetics through its Allergan portfolio. For more information about AbbVie, please visit www.abbvie.com. A wealth of resources is also available on their social media platforms, including Facebook, Instagram, X (formerly Twitter), YouTube, and LinkedIn.

In Japan, AbbVie primarily focuses on the development and provision of products in immune diseases, liver diseases, neuroscience, cancer, eye care, and aesthetic medicine. More details can be found at www.abbvie.co.jp. Their presence on Facebook and YouTube also offers valuable insights.